

GOVERNMENT OF NCT of DELHI  
DEPARTMENT OF HEALTH & FAMILY WELFARE

ORDER

F No. PA/SSSHFW/2021/Tocilizomab/CD-112648651/SSSB/w/ Dated :13.5.2021

237-246

In order to streamline and systematize the distribution of Tocilizumab injections, to prevent the indiscriminate use of this injection and to establish a transparent, efficient and time-bound system of distribution of this drug to the needy and hospitalized COVID-19 patients on clinically approved evidence-based grounds and ethical principle of distributive justice across Delhi, the competent authority has approved the constitution of a 3 member Technical Expert Committee (TEC) as follows:

- 1) Dr. M. K. Daga (Pulmonologist), as Chairman.
- 2) Dr. Manisha Aggarwal (Anesthesia Branch, MAMC)
- 3) Dr. S. Anuradha (Medicine Branch, MAMC)

2. Further, the following steps are prescribed to approve the distribution/supply of Inj. Tocilizumab to notified COVID Hospitals (Govt and Private) only for the treatment of COVID-19 patients:


i. **Application:** All the COVID Hospitals requiring Injection Tocilizumab for treatment of COVID-19 patients shall apply to the Technical Experts Committee.

ii. The application will be the Proforma (**Annexure-A**) to be sent to the TEC through notified e-mail or physical copy. No application without filled proforma or incomplete Proforma will be entertained.

iii. The TEC will meet twice every day (preferably 10-11am in the morning and 4-5 PM in the evening) to scrutinize the applications received and facilitate rapid decision making, as time is of the essence in such cases. The meetings can be held on a virtual/digital platform. The guiding principles for TEC shall be evidence based clinically approved parameters as well as principles of equity, distributive justice and transparency.

iv. DGHS shall coordinate with the TEEC and facilitate rapid decision making and also monitor the overall management of drug from approval till delivery to the Hospital concerned.

v. The decision of daily meetings will be conveyed to all the stakeholders through e-mail and reasons for refusal will be written and informed to the requisitioning Hospitals. A copy of the decision shall also be displayed on the website of DGHS/Health Department.





vi. On recommendation of the TEC, the o/o DGHS shall issue the drug to the authorized representative of the Government Hospital/institution concerned or the CFA/Stockist shall release to the authorized representative of the Private Hospital concerned (in this case, on payment basis) as the case may be.

vii. DGHS and all the CFAs/Stockists will ensure the issuance of drug on same day to the Government and Private Hospital concerned. Respectively, All relevant records shall be maintained by o/oDGHS.

viii. The concerned Govt/Private hospital will submit report regarding usage of drug for the approval patient only.

ix. It shall be the personal responsibility of the Hospital Administration of the institutes requisitioning Tocilizumab to ensure appropriate use of prescription medicine, prevent any misuse/pilferage, coordination with health authorities and to keep proper records so that they are available for audit purpose later.

x. The distribution of Tocilizumab Injections will be made up till the stock remains as per the allocation of Government of India. No waiting list shall be made.

xi. For arrival of fresh stocks applications will be called afresh after notifying all hospitals for arrival of stocks.

xii. In exceptional circumstances Pr Secretary (H&FW) may allocate injections to any Government Hospitals/ Hospitals run by Government Agencies on special recommendation by the treating doctor.

*Raj Kumar*  
13/5/2024

Raj Kumar

Spl. Secretary, (H&FW)

To,

1. Director, DGHS, GNCTD
2. TEC Members, GNCTD
3. MS/Nodal Officer of all Government Hospitals, GNCTD
4. MS/Nodal Officer of all Private Hospitals, GNCTD
5. All C&FAs/Stockiest of Tocilizumab

Copy for information :

1. So to CS, GNCTD
2. State Nodal Officer, GNCTD
3. PS to Pr. Secretary, (H&FW), GNCTD
4. Drug Controller, GNCTD

Copy for information to :

1. Secretary to Health Minister, HFW, GNCTD

*Raj Kumar*  
13/5/2024

Raj Kumar

Spl. Secretary, (H&FW)



**GOVERNMENT OF NCT of DELHI  
DEPARTMENT OF HEALTH & FAMILY WELFARE**

**Technical Expert Committee to decide about Tocilizumab**

Only a multidisciplinary team or 3 members team consisting of physician involved in COVID patient care (to be signed by at least two) can recommend the use of Tocilizumab/Immunomodulator therapy.

The following parameters have to be considered and recorded:

Condition	Yes/No	Condition	Yes/No
Rapid deterioration		Coexistent infection other than COVID-19	
RR>30 bpm		PaO <sub>2</sub> /FiO <sub>2</sub> > 300 mm Hg; chronic glucocorticoid use	
SaO <sub>2</sub> <93% on room air & CRP>=75 mg/L.		H/o another ILG inhibitor in present admission.	
PaO <sub>2</sub> /FiO <sub>2</sub> < 300 mm Hg in room air, and		H/O severe allergic reactions to monoclonal antibodies	
Lung infiltrates > 50% within 24-48 h		ANC<500 per ML; platelets < 50x10 <sup>9</sup>	
Invasion or noninvasive mechanical ventilation, including through HFNC with flow> 30 L/min & FiO <sub>2</sub> >0.4		Active diverticulitis, IBD, or another symptomatic gastrointestinal tract condition that might predispose patients to bowel perforation	
Vasopressor or inotrope		Severe haematological, renal, or liver function impairment.	

Investigations	Result	Condition	Result
CRP		S Creatinine	
SGOT/SGPT		CT severity score (if available)	
Blood culture (if available)		S Procalcitonin (if available)	

*Q12*



This is certified that

Mr/Ms/Mrs .....

S/O/D/oW/o .....

Aged.....yrs

Address ..... Presently admitted in

Institution/Hospital

(name).....Address.....

Hospital admission ID No

.....DOA.....(DD/MM/Year) is

suffering from COVID-19 and is found to be an eligible for Tocilizumab  
(.....mg)

Treating Hospital contact person :

Name	Contact No.	Email

Intensivist /Anaesthesiologist  
Physician/Respiratory physician

Place:

Date:

